6 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 6 of 6 clinical reviews.
A deep dive into the FOURIER trial's primary and secondary endpoint results for evolocumab, including effect sizes, confidence intervals, time-course patterns, and subgroup analyses in 27,564 patients with established ASCVD.
Deep-dive into FOURIER trial pre-specified and post-hoc subgroup analyses for evolocumab, examining which patient populations saw the greatest and smallest MACE reductions by age, sex, BMI, baseline LDL-C, and more.
A deep-dive overview of the FOURIER trial, the landmark 27,564-patient RCT that proved evolocumab (a PCSK9 inhibitor) reduces heart attacks and strokes in patients already taking statins.
A clinical deep-dive into the enrollment biases, short follow-up, generalizability gaps, statistical nuances, and conflict-of-interest concerns raised about the FOURIER evolocumab cardiovascular outcomes trial.
A deep-dive into the FOURIER trial's randomization, blinding, endpoint adjudication, statistical design, and how each methodological choice shapes interpretation of evolocumab's 15% MACE reduction.
A deep-dive into the FOURIER trial of evolocumab (Repatha) in established ASCVD, examining how the 15% MACE reduction reshaped guidelines, prescribing patterns, and patient selection for PCSK9 inhibitors.